FRONTIER-2 study results show IL-23 inhibitor promising in psoriasis

Dr. Feldman is involved in various research, speaking, and consulting activities with numerous pharmaceutical companies in the dermatology field, including AbbVie, Amgen, Eli Lilly, and Pfizer, among others. He is also the founder and part owner of Causa Research and holds stock in Sensal Health. This information was disclosed in an interview with Healio.

Source link